Alzheimers-Immune System Connection Revealed
An international research team reports that they have identified a second gene variant that confers a high risk of acquiring the more common, late-onset form of Alzheimers disease.
An international research team reports that they have identified a second gene variant that confers a high risk of acquiring the more common, late-onset form of Alzheimer’s disease. The gene was also found to predict poorer cognitive function in older individuals who do not have Alzheimer’s disease, according to the investigators.
The study, carried out by deCODE Genetics and Illumina, along with scientists from the National Hospital of Iceland and collaborators from Holland, Germany, and the U.S., was reported today in the New England Journal of Medicine.
“The discovery of variant TREM2 is important because it confers high risk for Alzheimer’s and because the gene’s normal biological function has been shown to reduce [the] immune response that may contribute to the disease,” explained lead author Kari Stefánsson, M.D., Dr. Med., CEO of deCODE Genetics. “These combined factors make TREM2 an attractive target for drug development.”
While a number of common, low-risk variants have been reported to associate with late-onset Alzheimer’s, the ε4 allele of Apolipoprotein E, originally discovered as a risk factor for the disease in 1993, has been the most important sequence variant because of its prevalence in the population and the size of its effect on risk.
TREM2, while rarer in the general population than the ApoE ε4 allele, confers a comparable risk of the disease and plays a significant role in the central nervous system. In preclinical studies, TREM2 has been found to regulate the clearing of cell debris and amyloid protein, a component of the amyloid plaques associated with Alzheimer's disease. TREM2 has also been shown to exercise a regulatory control of inflammation, which has been associated with Alzheimer’s and cognitive decline.
“Our findings strongly implicate variant TREM2 in the pathogenesis of Alzheimer’s disease,” said Dr. Stefánsson. “Reduced TREM2 activity may lead to brain damage through increased inflammatory response.”
After carrying out a large number of genome sequencing and genotyping operations, deCODE researchers identified approximately 41 million markers, including 191,777 functional variants, from 2,261 Icelandic samples. These variants were then analyzed against the genomes of 3,550 persons with Alzheimer’s disease and a control population over the age of 85 without a diagnosis of the disease. The association analysis used to identify the variant TREM2 in the Icelandic population was then replicated against other control populations with Alzheimer’s disease maintained in the U.S., Germany, the Netherlands, and Norway.
“Using this approach, we have recently reported variants that greatly influence the risk of developing other diseases, including ovarian cancer, gliomas, gout, and sick sinus syndrome,” continued Dr. Stefánsson. “So-called big data research has evolved to a new level of sophistication due to new research tools, access to expanded and high-quality genomic data sets, and certainly the profound analytic skill level of investigators now combining sequence data and biological knowledge to find drug targets.”
The issue of which genes are involved in early-onset and late-onset Alzheimer’s is not a clearcut division. Last February, scientists the Washington University School of Medicine in St. Louis reported in PloS One that rare variants of three genes associated with the early onset of the disease—APP, PSEN1, PSEN2—have also been discovered in patients with the late-onset form.
“The presence of variants in these genes…demonstrates that factors other than the mutation can impact the age at onset,” wrote the scientists. They believe this finding could eventually lead to changes in how the disease is classified.
Related News
-
News CPHI Podcast Series: The power of proteins in antibody drug development
In the latest episode of the CPHI Podcast Series, Lucy Chard is joined by Thomas Cornell from Abzena to discuss protein engineering for drug design and development. -
News Amgen sues Samsung biologics unit over biosimilar for bone disease
Samsung Bioepis, the biologics unit of Samsung, has been issued a lawsuit brought forth by Amgen over proposed biosimilars of Amgen’s bone drugs Prolia and Xgeva. -
News CPHI Podcast Series: Why we need to consider women in clinical trials
The latest episode of the CPHI Podcast Series with Lucy Chard covers women's health, specifically women's representation in clinical trials, the associated bias, and the impacts on health for this population. -
News US FDA does not approve MDMA therapy for PTSD, requests more data
The MDMA-based therapeutic developed by Lykos Therapeutics, a California-based Public Benefit Corporation (PBC), has been reviewed and unapproved by the US FDA. The regulator has requested additional phase III trial data for further safety and efficacy... -
News Novartis and Viatris latest facing lawsuit over HeLa cell misuse
Global pharmaceutical companies Novartis and Viatris are the latest hit with a lawsuit claim pertaining to alleged misuse of the ‘HeLa’ cell line from the estate of woman whose cancerous tissue cells were taken without consent. -
News Sanofi invests billions into Frankfurt insulin production site
French pharmaceutical company Sanofi have announced an investment of EUR1.3 billion at their existing BioCampus site in Frankfurt am Main for the expansion of insulin production. -
News Novel oral Type 1 diabetes drug gains US FDA IND designation
A University of Alabama at Birmingham startup has gained FDA clearance for Investigational New Drug clinical trials for an oral Type 1 diabetes drug, a milestone for diabetes treatment. -
News A Day in the Life of a Vice President in R&D & Engineering
In the Day in the Life of Series, we've already had the chance to get to know a range of people in various roles in the pharma industry. In the latest interview we get a glimpse into the R&D side of things from Jennifer Sorrells, Vice Presiden...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance